These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6177952)

  • 1. The nitroglycerin polymer gel matrix system: a new method for administering nitroglycerin evaluated with plasma nitroglycerin levels.
    Colfer H; Stetson P; Lucchesi BR; Wagner J; Pitt B
    J Cardiovasc Pharmacol; 1982; 4(3):521-5. PubMed ID: 6177952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic and hormonal response to transdermal nitroglycerin in normal subjects and in patients with congestive heart failure.
    Olivari MT; Carlyle PF; Levine TB; Cohn JN
    J Am Coll Cardiol; 1983 Nov; 2(5):872-8. PubMed ID: 6415142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained beneficial hemodynamic responses to large doses of transdermal nitroglycerin in congestive heart failure and comparison with intravenous nitroglycerin.
    Rajfer SI; Demma FJ; Goldberg LI
    Am J Cardiol; 1984 Jul; 54(1):120-5. PubMed ID: 6430054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the safety and efficacy of topical nitroglycerin ointment to facilitate venous cannulation.
    Griffith P; James B; Cropp A
    Nurs Res; 1994; 43(4):203-6. PubMed ID: 8047423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-hemodynamic studies of transdermal nitroglycerin in congestive heart failure.
    Armstrong PW
    J Am Coll Cardiol; 1987 Feb; 9(2):420-5. PubMed ID: 3100600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapidly developing tolerance to transdermal nitroglycerin in congestive heart failure.
    Jordan RA; Seth L; Casebolt P; Hayes MJ; Wilen MM; Franciosa J
    Ann Intern Med; 1986 Mar; 104(3):295-8. PubMed ID: 3080935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitroglycerin concentration in plasma: comparison between transdermal therapeutic system and ointment.
    Chu LC; Gale RM; Schmitt LG; Shaw JE
    Angiology; 1984 Sep; 35(9):545-52. PubMed ID: 6435484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma concentrations and haemodynamic effects of nitroglycerin during and after intravenous infusion in healthy volunteers.
    Imhof PR; Sieber A; Hodler J; Müller P; Ott B; Fankhauser P; Chu LC; Gérardin A
    Eur J Clin Pharmacol; 1982; 23(2):99-106. PubMed ID: 6814928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human pharmacological studies of a new transdermal system containing nitroglycerin.
    Müller P; Imhof PR; Burkart F; Chu LC; Gérardin A
    Eur J Clin Pharmacol; 1982; 22(6):473-80. PubMed ID: 6813125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation of time course of plasma nitroglycerin levels to echocardiographic, arterial pressure and heart rate changes after sublingual administration of nitroglycerin.
    Wei JY; Reid PR
    Am J Cardiol; 1981 Oct; 48(4):778-82. PubMed ID: 6792895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma levels of nitroglycerin generated by three nitroglycerin patch preparations, Nitradisc, Transiderm-Nitro and Nitro-Dur and one ointment formulation, Nitrobid.
    McAllister A; Mosberg H; Settlage JA; Steiner JA
    Br J Clin Pharmacol; 1986 Apr; 21(4):365-9. PubMed ID: 3085698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal nitroglycerin in angina pectoris.
    Parker JO; Fung HL
    Am J Cardiol; 1984 Sep; 54(6):471-6. PubMed ID: 6433687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of the bioavailability of nitroglycerin from a transdermal therapeutic system (Nitroderm TTS).
    Imhof PR; Vuillemin T; Gérardin A; Racine A; Müller P; Follath F
    Eur J Clin Pharmacol; 1984; 27(1):7-12. PubMed ID: 6436032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma nitroglycerin concentrations and hemodynamic effects of sublingual, ointment, and controlled-release forms of nitroglycerin.
    Curry SH; Kwon HR; Perrin JH; Culp JR; Pepine CJ; Yu WC; Stevens JL
    Clin Pharmacol Ther; 1984 Dec; 36(6):765-72. PubMed ID: 6437723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dose and ointment application technique on nitroglycerin plasma concentrations.
    Iafrate RP; Yost RL; Curry SH; Gotz VP; Caranasos GJ
    Pharmacotherapy; 1983; 3(2 Pt 1):118-24. PubMed ID: 6406987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycerol trinitrate (nitroglycerin) plasma concentrations achieved after application of transdermal therapeutic systems to healthy volunteers.
    Gerardin A; Gaudry D; Moppert J; Theobald W; Fankhauser P
    Arzneimittelforschung; 1985; 35(2):530-2. PubMed ID: 3922382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative bioavailability of a new transdermal nitroglycerin delivery system.
    Noonan PK; Gonzalez MA; Ruggirello D; Tomlinson J; Babcock-Atkinson E; Ray M; Golub A; Cohen A
    J Pharm Sci; 1986 Jul; 75(7):688-91. PubMed ID: 3093667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exercise capacity with transdermal nitroglycerin in patients with stable angina pectoris.
    Naafs MA; de Boer AC; Koster RW; Klazen CW; Dunning AJ
    Eur Heart J; 1984 Sep; 5(9):705-9. PubMed ID: 6437815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma nitroglycerin levels after sublingual, oral and topical administration.
    Blumenthal HP; Fung HL; McNiff EF; Yap SK
    Br J Clin Pharmacol; 1977 Apr; 4(2):241-2. PubMed ID: 405030
    [No Abstract]   [Full Text] [Related]  

  • 20. Variable glyceryl dinitrate formation as a function of route of nitroglycerin administration.
    Noonan PK; Benet LZ
    Clin Pharmacol Ther; 1987 Sep; 42(3):273-7. PubMed ID: 3113806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.